Vascular Biogenics Ltd (VBLT)

[Oren1976]

First VB-111 was tested as monotherapy with ph2 compelling results in Thyroid cancer, refractory thyroid cancer patients that were desperate after all therapy failed and stay alive until today very long term with no signs of cancer under monotherapy vb-111. it was also tested as monotherapy in lung cancer , neuroendocrine cancer and renal cancers with a patient alive over 7 years from ph1 mono so the no mono part of what you wrote is wrong.

Second it is obvious to me should be to you and of course it will be obvious to big pharma that if gbp results are positive and the ph2 was translated to phase 3 success then all the ph2 in easier indication which showed better results in the ph2 like thyroid and ovarian will pass the ph3 so this is also not an issue

If there is a buyout the buyout is for all solid tumor, I know it and if I know it big pharma knows it .